Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37–51.

PubMed  Article  Google Scholar 

Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol. 2010;84(20):10448–56.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425–37.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Beck ES, Cortese I. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol. 2020;40:19–27.

CAS  PubMed  Article  Google Scholar 

Lambert N, El Moussaoui M, Maquet P. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: identifying relevant outcome factors. Eur J Neurol. 2021;28(11):3814–9.

PubMed  Article  Google Scholar 

Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain. 1958;81(1):93–111.

CAS  PubMed  Google Scholar 

Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59–68.

CAS  PubMed  Article  Google Scholar 

Casado JL, Corral I, García J, Martinez-San Millán J, Navas E, Moreno A, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis. 2014;33(2):179–87.

CAS  PubMed  Article  Google Scholar 

Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77–83.

PubMed  Article  Google Scholar 

Antinori A, Cingolani A, Lorenzini P, Giancola ML, Uccella I, Bossolasco S, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol. 2003;9(Suppl 1):47–53.

CAS  PubMed  Article  Google Scholar 

•• Summers NA, Kelley CF, Armstrong W, Marconi VC, Nguyen ML. Not a disease of the past: a case series of progressive multifocal leukoencephalopathy in the established antiretroviral era. AIDS Res Hum Retroviruses. 2019;35(6):544–52. (This is a case series that documents the continued impact of PML and PML-IRIS in people living with HIV.)

PubMed  PubMed Central  Article  Google Scholar 

•• Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019;6(6). This is a hospital-based cohort study of PML that highlights shifts in the epidemiology of this disease.

Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol. 2003;9(Suppl 1):38–41.

CAS  PubMed  Article  Google Scholar 

•• Graf LM, Rosenkranz SC, Hölzemer A, Hagel C, Goebell E, Jordan S, et al. Clinical presentation and disease course of 37 consecutive cases of progressive multifocal leukoencephalopathy (PML) at a German tertiary-care hospital: a retrospective observational study. Front Neurol. 2021;12: 632535. This is a hospital-based cohort study which describes the underlying risk factors, clinical course, and treatment strategies among 37 cases of PML.

PubMed  PubMed Central  Article  Google Scholar 

Tada H, Rappaport J, Lashgari M, Amini S, Wong-Staal F, Khalili K. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci U S A. 1990;87(9):3479–83.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Daniel DC, Kinoshita Y, Khan MA, Del Valle L, Khalili K, Rappaport J, et al. Internalization of exogenous human immunodeficiency virus-1 protein, Tat, by KG-1 oligodendroglioma cells followed by stimulation of DNA replication initiated at the JC virus origin. DNA Cell Biol. 2004;23(12):858–67.

CAS  PubMed  Article  Google Scholar 

Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.

CAS  PubMed  Article  Google Scholar 

Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–62.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–27.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36(10):2638–78.

PubMed  PubMed Central  Article  Google Scholar 

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–45.

PubMed  Article  Google Scholar 

McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.

CAS  PubMed  Article  Google Scholar 

Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234(10):16824–37.

CAS  PubMed  Article  Google Scholar 

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7.

CAS  PubMed  Article  Google Scholar 

Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–21.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, et al. T Cell Factor 1-Expressing Memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415–27.

CAS  PubMed  Article  Google Scholar 

•• Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion.’ Nat Rev Immunol. 2019;19(11):665–74. This review collects the viewpoints of experts in the field, providing a comprehensive discussion of definitions and biomakers of T cell exhaustion and the implications for treatments targeting the underlying pathways.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998-1013.e20.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8. Nat Immunol. 2019;20(3):326–36.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Castelli V, Lombardi A, Palomba E, Bozzi G, Ungaro R, Alagna L, et al. Immune checkpoint inhibitors in people living with HIV/AIDS: facts and controversies. Cells. 2021;10(9).

Coghill AE, Pfeiffer RM, Shiels MS, Engels EA. Excess Mortality among HIV-Infected Individuals with Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(7):1027–33.

PubMed  PubMed Central  Article  Google Scholar 

Wang CC, Silverberg MJ, Abrams DI. Non-AIDS-defining malignancies in the HIV-infected population. Curr Infect Dis Rep. 2014;16(6):406.

PubMed  PubMed Central  Article  Google Scholar 

Vora KB, Ricciuti B, Awad MM. Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. Sci Rep. 2021;11(1):6637.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol. 2011;29(32):e792–4.

PubMed  Article  Google Scholar 

Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5(7):1049–54.